Skip to main content

Table 2 Predictors of growth impairment in patients with cSLE

From: Long-term growth and final adult height outcome in childhood-onset systemic lupus erythematosus

Predictive factors

Univariate

Multivariate

OR (95% CI)

P value

OR (95% CI)

P value

From time at diagnosis to achieving FAH (N = 106)

 Male

5.33 (1.85–15.37)

0.002a

7.07 (2.11–23.74)

0.002a

 Duration of disease prior to menarche/adult voice appearance (y)

1.27 (1.05–1.53)

0.016a

1.26 (1.02–1.56)

0.033a

 Cumulative dose of corticosteroids ≥300 mg/kgb

3.87 (1.07–14.08)

0.040a

3.91 (0.93–16.37)

0.058

 Height impairment at diagnosisc

3.00 (1.04–8.59)

0.041a

3.07 (0.92–10.25)

0.068

From time at diagnosis to the late phase of puberty (N = 76)

 Male

5.14 (1.59–16.62)

0.006a

8.87 (2.12–37.17)

0.003a

 Cumulative dose of corticosteroids ≥230 mg/kgb

4.10 (1.22–13.75)

0.022a

6.99 (1.63–30.02)

0.009a

  1. aP < 0.05 was set as significance; bPrednisolone equivalent; cHeight impairment: height Z-score less than −1.5; FAH: final adult height